MedTrace Logo

Endothelial Dysfunction and Diabetes

NCT01097551 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 38

Last updated 2012-07-03

No results posted yet for this study

Summary

The aim of the study is to progress in the understanding of the early retinal vascular and neural abnormalities in patients with diabetes, using a new device, the Dynamic Vessel Analyzer. The Dynamic Vessel Analyzer allows to measure the diameter of the retinal vessels and to assess how it varies in presence of various stimuli. Then, we will be able to assess if a vascular and/or a neural dysfunction is present early in patient with diabetes.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

DRUG

Trinitrin

Trinitrin: 2 sublingual pulverisations of 0.3 mg/dose

DRUG

Neosynephrine 10% collyrium

Neosynephrine 10% collyrium: 2 drops

DRUG

Iontophoresis with acetylcholine delivery

Iontophoresis with acetylcholine delivery

DEVICE

Dynamic Vessel Analyzer

Dynamic Vessel Analyzer

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Amélie LECLEIRE-COLLET, MD · Assistance Publique - Hôpitaux de Paris

  • Pascale MASSIN, MD, PhD · Assistance Publique - Hôpitaux de Paris

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01097551 on ClinicalTrials.gov